Medistem makes Alan Lewis CEO
This article was originally published in Scrip
Adult stem cell company Medistem has appointed Dr Alan Lewis CEO and a member of the board of directors. Dr Lewis has been a member of Medistem's scientific advisory board since January 2012. He has previously served as CEO of Signal Therapeutics, Novocell and the Juvenile Diabetes Research Foundation, and is currently a board member of BioMarin. He replaces Dr Thomas Ichim, who has served as CEO since 2008 and has now been appointed Medistem's president and chief scientific officer.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.